PHARNEXT
Regulatory News:
Pharnext (ISIN FR00111911287) (Paris:ALPHA), a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases, today announced that it has appointed René Goedkoop, M.D. as Chief Medical Officer and François Chamoun as General Counsel. Both Dr. Goedkoop and Mr. Chamoun bring highly valuable expertise in clinical development and legal affairs.
- René Goedkoop, Chief Medical Officer, has over 25 years of experience in worldwide clinical product development with emphasis on “first-in-class” therapeutic solutions for inflammatory diseases including rare CNS disorders, cancer and cardiovascular diseases. He worked in start-up and large biopharmaceutical companies such as Centocor, Eli Lilly, Serono, Modex or Apoxis, and directly interacted with key regulatory agencies (FDA, EMA, Korea, Japan and China). As an independent consultant, he conducted due diligences and helped develop business plans for de novo biotech companies for venture capital investors. Dr. Goedkoop received his M.D. at the University of Amsterdam followed by a residency in cardiopulmonary surgery.
- François Chamoun, General Counsel, has more than 15 years of legal affairs experience, covering the full value chain within private healthcare companies. Before joining Pharnext, Mr. Chamoun, as Head of Legal Affairs for a family office, participated in launching and securing funding for Steba Biotech, a biotechnology group in oncology. Previously, as Head of Legal Affairs, he participated in capitalistic restructuring activities for a holding company that owned the pharmaceutical company Laboratoires Negma-Lerads. He also managed legal affairs for Talento Ventures, a seed-capital fund, dedicated to new and innovative technologies. Mr. Chamoun holds a Masters Degree in business law and a D.J.C.E. from the University of Toulouse.
“I am delighted to welcome Dr. René Goedkoop as Chief Medical Officer and Mr. François Chamoun as General Counsel to Pharnext,” said Daniel Cohen, M.D., Ph.D., Co-Founder and Chief Executive Officer of Pharnext. “ Dr. Goedkoop’s deep expertise in clinical development strategy and implementation will be instrumental for us as we pursue the development of PXT3003, currently in Phase 3 for Charcot-Marie-Tooth disease type 1A, and also for PXT864 in Alzheimer’s disease and other neurological indications. Additionally, as Pharnext continues its growth following its recent IPO, the legal expertise of Mr. Chamoun in the healthcare sector will be critical. These two new executives will strengthen the management team and surely help us to reach our ultimate goal: give patients suffering from severe diseases with no valuable therapeutic alternatives access to more efficacious, safer and affordable treatments. ”
About Pharnext
Pharnext is an advanced clinical stage
biopharmaceutical company founded by renowned scientists and
entrepreneurs including Professor Daniel Cohen, a pioneer in modern
genomics. Pharnext focuses on neurodegenerative diseases and has two
lead products in clinical development: PXT3003 is currently in an
international Phase 3 trial for the treatment of Charcot-Marie-Tooth
disease type 1A and benefits from orphan drug status in Europe and the
United States. PXT864 has generated positive Phase 2 results in
Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery
paradigm: pleotherapy. The Company identifies and develops synergic
combinations of repositioned drugs at low dose. These “pleodrugs” offer
several key advantages: efficacy, safety, and intellectual property
including several composition of matter patents already granted. The
Company is supported by a world-class scientific team.
The company Pharnext is listed on Euronext Alternext Stock Exchange in Paris (ISIN code: FR00111911287).
For more information, please visit www.pharnext.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160725006093/en/
Contact:
Pharnext
Daniel Cohen, M.D., Ph.D.
Chief Executive
Officer
contact@pharnext.com
+33
(0)1 41 09 22 30
or
NewCap
Investors Relations
Julie
Coulot
pharnext@newcap.eu
+33
(0)1 44 71 20 40
or
Media Relations (Europe)
Alize
RP
Caroline Carmagnol
Margaux Pronost
pharnext@alizerp.com
+33
(0)1 44 54 36 64
or
Media Relations (US)
Russo
Partners
Tony Russo, Ph.D.
Matt Middleman, M.D.
tony.russo@russopartnersllc.com
matt.middleman@russopartnersllc.com
+1
212-845-4251
+1 212-845-4272
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
30 Peer-Reviewed Studies Highlight Statistically Significant Health Benefits of Almased16.7.2025 09:15:00 CEST | Press release
Two recent, peer-reviewed clinical studies have found that Almased, a high-protein, low-glycemic meal replacement, delivers significant health benefits ranging from weight loss and improved metabolic health to anti-aging effects and enhanced quality of life. Both reviews synthesize 30 peer-reviewed clinical studies across three decades of scientific research, confirming that Almased is effective and safe for weight reduction, preservation of lean muscle mass, and cardiovascular health. The 2025 review in the American Journal of Biomedical Science & Research highlighted Almased’s efficacy and safety for wide groups of people including individuals seeking weight loss, those with metabolic syndrome or fatty liver, older adults needing to preserve muscle mass, and athletes or healthy-weight individuals who require additional high-quality protein. This review also discusses how Almased’s patented fermentation process produces over 80 bioactive peptides, including 2 times the average daily i
The Future of Connectivity Starts Here: Network X Returns to Paris October 14 - 1616.7.2025 09:00:00 CEST | Press release
Show Reconvenes at Paris Expo Porte de Versailles with Global Representation of Industry Leaders and Telco Experts Network X 2025 - the only event that brings the fixed and mobile markets together - returns to Paris Expo Porte de Versailles October 14 - 16. Built for telecom's top players, this annual show drives business model innovation and monetisation of next-generation fixed, mobile, satellite and transport networks through AI and cloud. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716595903/en/ Speaker on Headliners Stage at Network X 2024 New to Network X in 2025 are specialty events designed to deliver expert insights on trending topics including Data Center World and two Expo Stages for Fixed-Line and Mobile. More than 5,500 telco network infrastructure professionals will gather alongside 1,500 telcos to learn from six program tracks highlighting the latest advancements in Fibre, Wi-Fi Networks and Services, IP
Skechers AERO Series Opens New Chapter of Technical Running Innovation16.7.2025 09:00:00 CEST | Press release
New Collection Features an Evolution in Design that Cuts Through the Wind for That Aerodynamic Feel on Every Run Skechers Performance opens a new chapter of running innovation with the arrival of the Skechers AERO series. Named for the aerodynamic feel of the design, Skechers AERO represents the latest evolution of technical running shoes from the brand. The collection is engineered to deliver an exhilarating blend of speed, style and comfort to help runners cut through the wind and push beyond their personal bests while logging miles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716754749/en/ Introducing the Skechers AERO Series of technical running shoes: Skechers AERO Burst, Skechers AERO Spark, and Skechers AERO Tempo (L-R). “Recently launched in North America and Asia, the AERO Series leverages innovative technologies to elevate our signature comfort that’s now available to runners in Europe,” said Ben Stewart, Vic
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom